 |
Vol.52 No.2 contents | Japanese/English |
 | Full Text of PDF (275K) Article in Japanese |
- Review Article -
Review of Clinical Studies of Stereotactic Body Radiotherapy for Stage I Non-small Cell Lung Cancer
Hiroshi Onishi1, Tsutomu Araki11Department of Radiology, University of Yamanashi, Japan
Stereotactic body radiotherapy (SBRT) has been regularly applied mainly for inoperable patients with stage I non-small cell lung cancer from approximately 1995, and various clinical trials have been performed in Japan. Uematsu et al. (2001) reported that the 3-year local control and overall survival rates of SBRT (50-60 Gy in 10 fractions) were 94% and 66%, respectively. Nagata et al. (2005) reported that the 3-year overall survival rate of SBRT (48 Gy in 4 fractions) was 83% in stage IA and 72% in stage IB. Onishi et al. reported that both local control and survival rates were better with a biologically effective dose of 100 Gy or more than those given less than 100 Gy in a multi-institutional retrospective study in Japan. In the USA, Timmerman et al. reported that the maximum tolerable dose was 60 Gy in 3 fractions in a phase I study, and the 3-year local control and overall survival rates were 98% and 56%, respectively, in a phase II trial using the same protocol (RTOG0236). In Japan, a phase II trial of SBRT with 48 Gy in 4 fractions for stage IA (JCOG0403) has been completed, with a total enrollment of 165 patients, and the results of the operable patients subgroup was presented in 2010. Enrollment for a phase II trial for operable patients (RTOG0618) has also been completed.
key words: Stereotactic body radiotherapy, Non-small cell lung cancer, Stage I, Clinical trial
JJLC 52 (2): 168-173, 2012
